MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
264.35%
Quick Ratio
264.35%
Cash Ratio
158.83%
Debt to Asset Ratio
41.53%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Research and development supplie...
    • Operating lease right-of-use ass...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable and accrued exp...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
3,515
1,482
4,894
4,867
Research and development supplies and other current assets
1,807
-
-
-
Prepaid expenses
528
1,020
1,455
373
Other current assets
-
403
0
-
Total current assets
5,850
2,905
6,349
5,240
Total property and equipment at cost
1,290
1,290
1,290
1,290
Less accumulated depreciation
580
514
448
382
Property and equipment, net
710
776
842
908
Operating lease right-of-use asset, net
1,321
2,209
2,380
2,548
Other assets
48
48
48
48
Total assets
7,929
5,938
9,619
8,744
Accounts payable and accrued expenses
1,821
850
945
1,069
Operating lease liability, short-term
258
723
706
643
Loan payable
124
246
-
-
Sepa put option liability
10
10
108
437
Short-term convertible debt
-
-
0
4,573
Total current liabilities
2,213
1,829
1,759
6,722
Operating lease liability, long-term
1,080
1,509
1,704
1,897
Total liabilities
3,293
3,338
3,463
8,619
Preferred stock, value
0
0
0
-
Voting common stock, 0.00001 par value 300,000,000 shares authorized as of june 30, 2026 and december 31, 2025 6,080,560 shares and 3,325,986 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
1
1
1
-
Additional paid-in capital
67,916
61,763
60,319
51,045
Accumulated deficit
-63,281
-59,164
-54,164
-50,920
Total stockholders equity
4,636
2,600
6,156
125
Total liabilities and stockholders equity
7,929
5,938
9,619
8,744
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$3,515K (-60.26%↓ Y/Y)Research and developmentsupplies and other...$1,807K Prepaid expenses$528K (-60.39%↓ Y/Y)Total property andequipment at cost$1,290K (0.47%↑ Y/Y)Total current assets$5,850K (-42.52%↓ Y/Y)Operating leaseright-of-use asset, net$1,321K (-51.33%↓ Y/Y)Property and equipment,net$710K (-26.58%↓ Y/Y)Other assets$48K (0.00%↑ Y/Y)Less accumulateddepreciation$580K (82.97%↑ Y/Y)Total assets$7,929K (-42.99%↓ Y/Y)Total liabilities andstockholders equity$7,929K (-42.99%↓ Y/Y)Total stockholdersequity$4,636K (439.07%↑ Y/Y)Total liabilities$3,293K (-74.76%↓ Y/Y)Accumulated deficit-$63,281K (-40.18%↓ Y/Y)Additional paid-in capital$67,916K (47.64%↑ Y/Y)Total currentliabilities$2,213K (-79.82%↓ Y/Y)Operating leaseliability, long-term$1,080K (-48.15%↓ Y/Y)Voting common stock,0.00001 par value...$1K Accounts payable andaccrued expenses$1,821K (1.11%↑ Y/Y)Operating leaseliability, short-term$258K (-58.85%↓ Y/Y)Loan payable$124K Sepa put optionliability$10K (-97.87%↓ Y/Y)

FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc. (FBLG)